HARBIN, China, April 10, 2012 /PRNewswire-Asia/ -- China Botanic
Pharmaceutical Inc. (NYSE AMEX: CBP) ("China Botanic" or the
"Company"), a developer, manufacturer and distributor of botanical
products, bio-pharmaceuticals and traditional Chinese medicines
("TCM") in China, today announced
the results of its annual general meeting of stockholders ("Annual
Meeting") held on Tuesday, April 10,
2012 (Beijing Standard Time) in Harbin, China.
At the Annual Meeting, stockholders elected directors Messrs.
Shaoming Li, Zack Pan,
Bingchun Wu, Changxiong Sun, and Dianjun
Pi to serve on the Board of Directors of the Company.
Stockholders also ratified the appointment of Windes &
McClaughry Accountancy Corporation as the independent registered
public accounting firm of the Company for the fiscal year ending
October 31, 2012.
About China Botanic Pharmaceutical Inc.
China Botanic Pharmaceutical Inc. is engaged in the research,
development, manufacturing, and distribution of botanical products,
bio-pharmaceutical products, and traditional Chinese medicines
("TCM"), in the People's Republic of
China. All of the Company's products are produced at its
three GMP-certified production facilities in Ah City, Dongfanghong
and Qingyang. The Company distributes its botanical anti-depression
and nerve-regulation products, biopharmaceutical products, and
botanical antibiotic and OTC TCMs through its network of over 3,000
distributors and over 70 sales centers across 24 provinces in
China. For more information,
please visit www.renhuang.com.
Safe Harbor Statement
This press release contains certain statements that may include
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements are based
upon management's beliefs, assumptions and expectations of the
Company's future operations and financial performance, taking into
account the information currently available to management. These
statements are not statements of historical fact. Forward-looking
statements involve risks and uncertainties, some of which are not
currently known that may cause actual results, performance or
financial condition to be materially different from the
expectations of future results, performance or financial condition
expressed or implied in any forward-looking statements. These
forward-looking statements are based on current plans and
expectations and are subject to a number of uncertainties
including, but not limited to, the Company's ability to manage
expansion of its operations effectively, and other factors detailed
in the Company's annual report on Form 10-K and other filings with
the Securities and Exchange Commission. The Company undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise. You are cautioned not to unduly rely on such
forward-looking statements when evaluating the information
presented herein.
Company Contact:
China Botanic Pharmaceutical Inc.
David Dong CFO
Email:david@renhuang.com
Ms. Portia Tan, IR Contact
Tel: 86-451-8260-2162
Email: ir@renhuang.com
SOURCE China Botanic Pharmaceutical Inc.